Zheng Haiqiong, Chen Yijin, Luo Qian, Zhang Jie, Huang Mengmeng, Xu Yulin, Huo Dawei, Shan Wei, Tie Ruxiu, Zhang Meng, Qian Pengxu, Huang He
Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, 310012, China.
Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, 311121, China.
Cell Regen. 2023 Sep 1;12(1):31. doi: 10.1186/s13619-023-00175-6.
Human pluripotent stem cells (hPSCs) have been suggested as a potential source for the production of blood cells for clinical application. In two decades, almost all types of blood cells can be successfully generated from hPSCs through various differentiated strategies. Meanwhile, with a deeper understanding of hematopoiesis, higher efficiency of generating progenitors and precursors of blood cells from hPSCs is achieved. However, how to generate large-scale mature functional cells from hPSCs for clinical use is still difficult. In this review, we summarized recent approaches that generated both hematopoietic stem cells and mature lineage cells from hPSCs, and remarked their efficiency and mechanisms in producing mature functional cells. We also discussed the major challenges in hPSC-derived products of blood cells and provided some potential solutions. Our review summarized efficient, simple, and defined methodologies for developing good manufacturing practice standards for hPSC-derived blood cells, which will facilitate the translation of these products into the clinic.
人类多能干细胞（hPSCs）已被认为是用于临床应用生产血细胞的潜在来源。在二十年的时间里，几乎所有类型的血细胞都可以通过各种分化策略从hPSCs成功生成。与此同时，随着对造血作用的深入了解，从hPSCs生成血细胞祖细胞和前体细胞的效率更高。然而，如何从hPSCs大规模生成用于临床的成熟功能细胞仍然很困难。在这篇综述中，我们总结了最近从hPSCs生成造血干细胞和成熟谱系细胞的方法，并阐述了它们在产生成熟功能细胞方面的效率和机制。我们还讨论了hPSC来源的血细胞产品中的主要挑战，并提供了一些潜在的解决方案。我们的综述总结了用于制定hPSC来源血细胞的良好生产规范标准的高效、简单且明确的方法，这将有助于将这些产品转化为临床应用。
